Cargando…

Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis

IMPORTANCE: The optimum duration of adjuvant trastuzumab among patients with early breast cancer is uncertain but of great therapeutic relevance. OBJECTIVE: To compare shorter durations with 1 year of adjuvant trastuzumab for patients with early breast cancer. DATA SOURCES: PubMed, Embase, Cochrane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gulia, Seema, Kannan, Sadhana, Badwe, Rajendra, Gupta, Sudeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445596/ https://www.ncbi.nlm.nih.gov/pubmed/32833018 http://dx.doi.org/10.1001/jamanetworkopen.2020.11777

Ejemplares similares

National Cancer Control Programme in India: Proposal for Organization of Chemotherapy and Systemic Therapy Services
por: Gulia, Seema, et al.
Publicado: (2016)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
por: Gulia, Seema, et al.
Publicado: (2016)

Effectiveness of a Decision Aid Plus Standard Care in Surgical Management Among Patients With Early Breast Cancer: A Randomized Clinical Trial
por: Joshi, Shalaka, et al.
Publicado: (2023)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Shorter course of trastuzumab: Caveat emptor
por: Venniyoor, Ajit
Publicado: (2011)

Corneal Cross-Linking: Evaluating the Potential for a Lower Power, Shorter Duration Treatment
por: Caruso, Ciro, et al.
Publicado: (2016)

Mammographic screening for breast cancer: Are the chickens coming home to roost?
por: Badwe, Rajendra A., et al.
Publicado: (2013)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer
por: Boyne, Devon J., et al.
Publicado: (2021)

Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer With Brain Metastases: Real-World Experience
por: Bhargava, Prabhat, et al.
Publicado: (2022)

Reply to S. Rastogi et al
por: Gulia, Seema, et al.
Publicado: (2016)

Authors’ Reply
por: Gupta, Sudeep, et al.
Publicado: (2014)

Is human papillomavirus vaccination likely to be a useful strategy in India?
por: Gupta, Sudeep, et al.
Publicado: (2013)

Geographical & seasonal variation in COVID-19 related mortality
por: Badwe, Rajendra A., et al.
Publicado: (2020)

Severe skin toxicity due to weekly paclitaxel administration
por: Kate, Shruti, et al.
Publicado: (2015)

Progesterone suppresses the invasion and migration of breast cancer cells irrespective of their progesterone receptor status - a short report
por: Godbole, Mukul, et al.
Publicado: (2017)

Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2020)

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
por: Cortés, Javier, et al.
Publicado: (2020)

218. Evaluation of Clinical Outcomes with Shorter Vs. Longer Duration of Treatment for Common Inpatient Bacterial Infections Associated with Bacteremia
por: Hojat, Leila, et al.
Publicado: (2019)

215. Shorter vs. Longer Duration of Treatment in Patients with Ceftriaxone-resistant and Ceftriaxone-susceptible Escherichia coli Bloodstream Infections
por: Mackow, Natalie A, et al.
Publicado: (2023)

Maintenance therapy with a poly (ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: updated individual patient data and trial-level meta-analysis
por: Gulia, S., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer
por: Aboutorabi, Ali, et al.
Publicado: (2015)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Shorter spontaneous fixation durations in infants with later emerging autism
por: Wass, Sam V., et al.
Publicado: (2015)

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial
por: Rugo, Hope S., et al.
Publicado: (2021)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Cost Effectiveness of Trastuzumab for Management of Breast Cancer in India
por: Gupta, Nidhi, et al.
Publicado: (2020)

Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis: A Randomized Clinical Trial
por: Scott, James G., et al.
Publicado: (2020)

CONcurrent ChEmotherapy and RadioTherapy in adjuvant treatment of breast cancer (CONCERT): a phase 2 study
por: Wadasadawala, Tabassum, et al.
Publicado: (2023)

Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective
por: Clarke, Caroline S., et al.
Publicado: (2017)

Deciphering the mechanisms of action of progesterone in breast cancer
por: Chakravorty, Gaurav, et al.
Publicado: (2023)

Shorter respiratory event duration is related to prevalence of type 2 diabetes
por: Guo, Junwei, et al.
Publicado: (2023)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Adjuvant trastuzumab: progress, controversies, and the steps ahead
por: Joy, A.A., et al.
Publicado: (2006)

Effectiveness of adjuvant trastuzumab in daily clinical practice
por: Matos, Erika, et al.
Publicado: (2014)

Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope
por: Prasad, Rajendra, et al.
Publicado: (2017)

MR elastography identifies regions of extracellular matrix reorganization associated with shorter survival in glioblastoma patients
por: Svensson, Siri Fløgstad, et al.
Publicado: (2023)

Oligometastatic breast cancer: A mini review
por: Rastogi, Sameer, et al.
Publicado: (2014)

Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer
por: Marinko, Tanja, et al.
Publicado: (2018)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5hc12ticb2gg4qq6lg2eif7j0n